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Summary
 
Trypanosoma cruzi
 
 is the causative agent of Chagas’ disease. The major protease, cruzain, is a tar-
get for the development of new chemotherapy. We report the first successful treatment of an
animal model of Chagas’ disease with inhibitors designed to inactivate cruzain. Treatment with
fluoromethyl ketone–derivatized pseudopeptides rescued mice from lethal infection. The opti-
mal pseudopeptide scaffold was phenylalanine-homophenylalanine. To achieve cure of infec-
tion, this pseudopeptide scaffold was incorporated in a less toxic vinyl sulfone derivative.
 
N
 
-methyl piperazine-Phe-homoPhe-vinyl sulfone phenyl also rescued mice from a lethal in-
fection. Six of the treated mice survived over nine months, three without further treatment.
Three mice that had entered the chronic stage of infection were retreated with a 20-d regimen.
At the conclusion of the experiments, five of the six mice had repeated negative hemacultures,
indicative of parasitological cure. Studies of the effect of inhibitors on the intracellular amasti-
gote form suggest that the life cycle is interrupted because of inhibitor arrest of normal auto-
proteolytic cruzain processing at the level of the Golgi complex. Parasites recovered from the
hearts of treated mice showed the same abnormalities as those treated in vitro. No abnormali-
ties were noted in the Golgi complex of host cells. This study provides proof of concept that
cysteine protease inhibitors can be given at therapeutic doses to animals to selectively arrest a
parasitic infection.
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C
 
hagas’ disease, the result of infection with the proto-
zoan parasite 
 
Trypanosoma cruzi
 
, is the leading cause of
heart disease in Latin America (1). Over 1.6 
 
3
 
 10
 
7
 
 people
are infected, up to 80% in endemic areas, and over 9 
 
3
 
 10
 
7
 
are at risk (2). By definition, the acute phase of Chagas’ dis-
ease lasts up to 60 d and parasites are easily detected by di-
rect examination of peripheral blood (3). Acute Chagas’
disease results in myocarditis in 
 
z
 
60% of patients with an
estimated 9% mortality occurring in endemic areas (4).
Chagasic encephalitis, not uncommon in children, is also
associated with immunosuppression and AIDS (5–7). Gas-
trointestinal megasyndromes are common especially in Bra-
zilian patients. Most chagasic patients die from heart failure
associated with cardiomyopathy during the chronic phase
of the disease (3, 8).
Therapy for Chagas’ disease is unsatisfactory. Because of
significant toxicity, chemotherapy with nifurtimox or benz-
nidazole must be carried out under close medical supervi-
sion. In addition to dermatotoxicity and digestive disorders,
benznidazole induces chromosomal damage in chagasic
children (9). Long-term use of nifurtimox and benznidazole
in humans has not been documented, but its association
with malignant lymphomas in experimental animals pre-
cludes prolonged treatment of patients including immuno-
compromised patients (10). Both compounds may shorten
the acute phase and decrease mortality, but they achieve
parasitologic cures in only 
 
z
 
60% of acute patients and are
not used during the chronic phase of the disease (10). Fi-
nally, a large gradient of susceptibility to nifurtimox and
benznidazole treatments ranging from 0–100% correlates
with geographic region and may delineate distribution of
drug-resistant 
 
T
 
.
 
 cruzi 
 
(8, 11, 12).
One approach to novel chemotherapy for Chagas’ dis-
ease has focused on the development of specific inhibitors
of cruzain (a.k.a. cruzipain, gp 57/51), the major cysteine
protease of 
 
T. cruzi 
 
(13–17). Diazomethane or fluoro-
methyl ketone (FMK)
 
1
 
 cysteine protease inhibitors (CPI)
 
1
 
Abbreviations used in this paper: 
 
Boc, butyloxycarbonyl; Bsn, benzyl suc-
cinic acid; CPI, cysteine protease inhibitors; F, phenylalanine; FMK, fluo-
romethyl ketone; hF, homophenylalanine; Mu, morpholine urea; Obzl,
O-benzyl; Pip, piperazine; tic, tetrahydroisoquinoline 3-carboxylic acid;
VAmBzl, valine acetamidomethylbenzyl; VS, vinyl sulfone; VS
 
f
 
, vinyl
sulfone phenyl; Yii, diiodo tyrosine; Z, benzyloxycarbonyl; p.o., per oral.
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that effectively blocked cruzain activity prevented growth
and differentiation of 
 
T
 
.
 
 cruzi
 
 in cell culture models of in-
fection (18–20). A new generation of CPI has been synthe-
sized with chemical modifications aimed at enhancing
specificity and
 
 
 
in vivo stability and minimizing toxicity.
We now report that CPI treatment rescued mice from the
acute phase of a lethal experimental 
 
T
 
.
 
 cruzi
 
 infection and
cleared parasitemia in chronically infected mice without
toxicity to the mammalian host. The inhibitors induced
major ultrastructural alterations leading to death of the in-
tracellular amastigote stage that were similar to those previ-
ously observed in the extracellular insect stage epimasti-
gotes after exposure to the same protease inhibitors (21).
 
Materials and Methods
 
Growth Inhibition of T. cruzi Amastigotes by CPI.
 
J774 macro-
phages were cultured in RPMI-1640 medium with 5% heat-
inactivated FCS (RPMI medium). For growth inhibition assays,
J774 macrophages were irradiated (3,000 rad) to arrest cell growth
and cultured on coverglasses within six-well plates for 24 h at
37
 
8
 
C. After infection with 
 
T
 
.
 
 cruzi
 
 trypomastigotes of the Y strain
for 3 h, monolayers were washed with RPMI medium and
treated with inhibitors at 20 
 
m
 
M in RPMI medium. Inhibitor
stocks were made at 20 mM in DMSO and all assays included
DMSO (0.01–0.02%, vol/vol) controls. FMK inhibitors (Mu-
F-hF-VS
 
f
 
, Mu-F-K-VS
 
f
 
, Mu-F-V-VS
 
f
 
, Mu-F-S(OBzl)-VS
 
f
 
,
Mu-L-hF-VS
 
f
 
, Mu-Yii-hF-VS
 
f
 
, Boc-tic-hF-VS, Mu-tic-hF-VS,
Mu-Y-hF-VS, Mu-F-hF-FMK, Mu-F-hF-VAmBzl, N-Pip-F-hF-
VS
 
f
 
, Z-F-A-FMK, Mu-bsu-hF-FMK, and Mu-F-hF-FMK) were
provided by Prototek (Dublin, CA) and vinyl sulfones were pro-
vided by Axys Pharmaceuticals (South San Francisco, CA). CPI
were evaluated in
 
 T
 
.
 
 cruzi
 
–infected macrophage cultures for 21–
30 d. Trypomastigote output, indicative of the completion of the
intracellular cycle, was then assayed in treated and untreated cul-
tures to determine growth inhibition of intracellular 
 
T
 
.
 
 cruzi
 
amastigotes (20).
After this initial inhibitor screen,
 
 T
 
.
 
 cruzi
 
–infected macrophages
were treated with 20 
 
m
 
M Mu-F-hF-VS
 
f
 
 and Mu-F-V-VS
 
f
 
for up to 76 h. Monolayers were washed, fixed with 4% paraform-
aldehyde, and then Giemsa stained at determined intervals. To
evaluate treatment, the percentage of infected macrophages and
the total number of intracellular amastigotes in 100 infected
macrophages were quantified. A decrease in the number of intra-
cellular generations indicated inhibition of intracellular growth of
 
T
 
.
 
 cruzi
 
 amastigotes and was calculated from the total number of
intracellular amastigotes per 100 infected macrophages (
 
n
 
 5 
 
3).
 
Effect of CPI on the Survival of T. cruzi–infected Mice.
 
3-wk-old fe-
male C3H mice weighing initially between 17–19 g were used in
all experiments. In the first experiment (see Fig. 1), mice (five an-
imals per lot) were infected with 10
 
5
 
 trypomastigotes of the Y
strain and treated with a 1-mg i.p. injection of FMK inhibitors
(Mu-F-hF-FMK, Mu-bsu-hF-FMK, and Z-F-A-FMK) twice
per day. Controls included intraperitoneal injection with equal
volume of DMSO. Treatment was initiated 24 h after infection
and continued until death of the animals or the end of the exper-
iment, as appropriate. Parasitemias were determined every 48 h
for each animal on alternating days from 5 
 
m
 
l of blood extracted
from the tail and diluted 1/4 (vol/vol) in RPMI medium. The
numbers of parasites per milliliter, calculated in a Neubauer
chamber, were expressed as a mean of two or three animals per
day. The experiment was terminated 18 d after infection.
Approximate dosing regimes and different inhibitor chemis-
tries were then analyzed (see Table 3, 
 
Experiment 1
 
). Mice (five
animals per lot) were infected (intraperitoneally) with 4 
 
3
 
 10
 
6
 
 tis-
sue culture–derived trypomastigotes. 24 h after infection, mice
were treated with two daily doses of 1 mg i.p. Mu-F-hF-FMK
and Mu-F-hF-VS
 
f
 
 for up to 16 d. In a third experiment (see Ta-
ble 3, 
 
Experiment 2
 
), animals were infected with 10
 
6
 
 trypomasti-
gotes and treated with the inhibitors with the same regimen for 12 d.
Finally (see Table 3, 
 
Experiment 3
 
), mice were infected with
10
 
5
 
 
 
T
 
.
 
 cruzi
 
 trypomastigotes and treated with three daily intra-
peritoneal doses of N-Pip-F-hF-VS
 
f
 
 (2.1 mg/d) for 24 d. Blood
(hemo) cultures of untreated controls (
 
n
 
 5 
 
6) and N-Pip-F-hF-
VS
 
f
 
–treated animals (
 
n
 
 5 
 
10) were performed 16, 22, and 46 d
after infection using arrested macrophages as host cells. In brief,
6-
 
m
 
l aliquots of blood were resuspended in RPMI medium with
5% FCS and antibiotics. Irradiated J774 macrophages were in-
fected with blood dilutions, and incubated for up to 30 d at 37
 
8
 
C
in a 5% CO
 
2
 
 atmosphere. Blood cultures were considered posi-
tive if 
 
T
 
.
 
 cruzi
 
 infected macrophages and/or free trypomastigotes
were observed. Hemocultures were considered negative if no in-
fected host cells and no free trypomastigotes were observed for up
to 30 d, after which macrophages died.
Six animals from Table 3, 
 
Experiment 3,
 
 survived the acute
phase of the infection. Three out of six mice had consistently
negative blood cultures while the remaining three out of six were
positive. After being allowed to establish chronic infection for 3 mo,
the latter three mice were retreated with three daily doses (2.1
mg/d i.p.) of N-Pip-F-hF-VS
 
f
 
 for 21 d (see Table 4, 
 
Experiment
4
 
). Hemocultures from the six animals were performed repeat-
edly as described above but with a larger volume of blood sam-
pled (6–50 
 
m
 
l).
 
T
 
.
 
 cruzi
 
–infected, CPI-treated mice, noninfected CPI-treated
mice, and untreated 
 
T
 
.
 
 cruzi
 
–infected animals were necropsied to
evaluate toxicity of the inhibitor regimen. Mice were weighed,
examined grossly, and all major organs also examined by routine
hematoxylin-eosin histopathology. The toxicity of Mu-F-hF-
VS
 
f
 
 and N-Pip-F-hF-VS
 
f
 
 was further evaluated in uninfected
C3H mice treated for 45 d with 4 mg/d i.p., and 12 mg/d per
oral (p.o.), respectively.
 
Fluorescence Microscopy to Determine the Effect of CPI in the Para-
site.
 
Irradiated macrophages were infected with 
 
T
 
.
 
 cruzi
 
 trypo-
mastigotes for 2 h at 37
 
8
 
C. Monolayers were washed 24 h after
infection and reincubated with or without the addition of the
CPI Mu-F-hF-VS
 
f
 
 (10 
 
m
 
M). After 48 h, culture medium con-
taining Bodipy FL ceramide (Molecular Probes, OR) was substi-
tuted for 15 min at 37
 
8
 
C. Monolayers were subsequently pro-
cessed according to manufacturer’s instructions and observed by
fluorescence microscopy (21).
 
Ultrastructure and Immunocytochemistry of T. cruzi Intracellular
Amastigotes. T
 
.
 
 cruzi
 
–infected, irradiated J774 macrophages were
treated or not with Mu-F-hF-VS
 
f
 
 (10 
 
m
 
M) for 48 h. Monolayers
were trypsinized, washed, fixed, and processed for electronmicros-
copy. Cells were fixed with 1.5% glutaraldehyde in 0.66 M sodium
cacodylate buffer, pH 7.4, at room temperature for 2 h, embedded
in EPONATE 12 (Ted Pella, Inc., Redding, CA), sectioned,
stained, and then observed with a Zeiss 10C electronmicroscope
(Carl Zeiss Inc., Thornwood, NY; reference 22). The techniques
(23) and reagents used for immunocytochemistry have been de-
scribed previously for 
 
T
 
.
 
 cruzi
 
 epimastigotes (21). Heart muscle
from a mouse treated 6 d after infection with Mu-F-hF-VS
 
f
 
 (2
mg/d i.p. for 3 d) was fixed and processed as described above.
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Confirmation of Inhibitor Targets by Labeled Inhibitor.
 
Irradiated J774
macrophages were infected with Y strain trypomastigotes and in-
cubated at 37
 
8
 
C for 48 h to allow intracellular development of
amastigotes. 
 
T
 
.
 
 cruzi–
 
infected macrophages, uninfected macro-
phage controls, and 
 
T. cruzi epimastigotes were radiolabeled with 20
mM [14C]Mu-F-hF-VSf for 2 h at 378C or 268C, as appropriate.
For competition experiments, duplicate cultures were treated
with 20 mM Mu-F-hF-VSf for 3 h before addition of the radio-
labeled inhibitor. Infected macrophages were scraped and centri-
fuged at 1,700 g for 12 min at 48C. Pellets were resuspended and
lysed in a tissue grinder to release intracellular amastigotes, centri-
fuged at 260 g for 5 min, and the amastigote-containing superna-
tant centrifuged at 2,000 g for 12 min. Amastigote pellets were
resuspended, transferred to Eppendorf tubes, and washed three
times with PBS before sonication. Radiolabeled, noninfected
macrophages and T. cruzi epimastigotes were sonicated as above.
Purified recombinant cruzain was also radiolabeled as a control.
Samples were boiled in sample buffer (24), electrophoresed in
10% acrylamide gels, and autoradiographed (21). Western blots
were developed with anti-cruzain antibody (21).
Results
Effect of CPI on the Intracellular Development of T. cruzi.
The efficacy of a number of CPI on the mammalian stages
of the life cycle of T. cruzi was evaluated as the percentage
of growth inhibition of intracellular amastigotes in the
presence of the inhibitors for up to 21 d (Table 1). The first
intracellular cycle of untreated controls was completed
within 6 d after infection. Mu-F-hF-VSf was the most ef-
fective compound and inhibited growth 100%. Mu-F-V-
VSf and BOC-tic-hF-VS, which are less effective inhibi-
tors of the protease itself, produced 30% and 60% growth
inhibition, respectively.
Based on this initial screening of inhibitors, Mu-F-hF-
VSf with Mu-F-V-VSf for comparison were further
tested (Table 2). 20 mM concentrations of Mu-F-hF-VSf
cured T. cruzi–infected macrophages. Although intracellular
amastigotes were still visible in Giemsa-stained cultures 24–
78 h after infection, their morphology was extremely ab-
normal 50 h after treatment. Cultures were amastigote free
after 12 d. No intracellular amastigotes or release of trypo-
mastigotes were observed in cultures treated for 12 d and
Table 1. Effect of Cysteine Protease Inhibitors on the Intracellular 
Cycle of T. cruzi In Vitro
Inhibitor (20 mM)
Percentage of
growth inhibition
None (control) 0
Mu-F-hF-VSf 100
Mu-F-K-VSf 0
Mu-F-V-VSf 33.4
Mu-F-S(OBzl)-VSf 16.6
Mu-L-hF-VSf 24.9
Mu-Yii-hF-VSf 16.6
BOC-tic-hF-VS 58.3
Mu-Y-hF-VS 24.9
Mu-F-hF-FMK .83
Mu-F-hF-VAmBzl 41.5
Growth inhibition of intracellular amastigotes by cysteine protease in-
hibitors. Irradiated J774 macrophages were infected with trypomasti-
gotes of the Y strain of T. cruzi. Cells were treated daily with 20 mM of
peptidomimetic inhibitors of cruzain. Cultures were observed daily by
contrast phase microscopy for #30 d. The first intracellular cycle of
controls was completed within 6 d.
Table 2. Effect of Two Vinyl Sulfone Inhibitors on the Intracellular Cycle of T. cruzi In Vitro
Treatment Duration
Percentage of
cells infected
Amastigotes per
100 infected cells
Number of
intracellular
generations
h
Control 18 38% 76 6 4 0
50 41% 1,004 6 6 3.3
72 45% 5,220 6 6 5.6
Mu-F-hF-VSf (20 mM) 18 41% 80 6 5 0
50 25% 42 6 5 0
76 22% 35 6 5 0
Mu-F-V-VSf (20 mM) 18 36% 72 6 6 0
50 35% 1,106 6 7 3.6
Effect of the cysteine protease inhibitors on the intracellular growth of T. cruzi amastigotes. Irradiated J774 macrophages were infected with T. cruzi
before treatment with Mu-F-hF-VSf and Mu-F-V-VSf. The percentage of infected cells, the total number of intracellular amastigotes in 100 in-
fected cells, and the number of intracellular generations of T. cruzi amastigotes are indicated. Because host cells were irradiated to prevent their repli-
cation, a decrease in percentage of cells infected and number of amastigotes/cell is indicative of parasite death and clearance. Mu-F-V-VSf treatment
had no effect on amastigote growth. Cells treated with Mu-F-hF-VSf were amastigote free after 12 d.
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maintained without CPI for up to 30 d in numerous inde-
pendent experiments, indicating that Mu-F-hF-VSf not
only blocked the intracellular development of T. cruzi, but
eventually eliminated all parasites. In contrast, amastigotes
divided at normal rate in the presence of the chemically re-
lated, but less effective inhibitor of cruzain, Mu-F-V-VSf.
Resolution of Acute Experimental Chagas’ Disease. Levels of
parasitemia in T. cruzi–infected C3H mice were first ana-
lyzed after treatment with Z-F-A-FMK, Mu-bsu-hF-
FMK, and Mu-F-hF-FMK (Fig. 1). These FMK inhibitors
were chosen based on results of tissue culture screens (20,
Table 1) and included a natural amino acid dipeptide (Z-
F-A-FMK) and pseudopeptides designed to increase in vivo
half-life (Mu-bsu-hF-FMK and Mu-F-hF-FMK). Control
animals died at day 12 after infection while all animals
treated with Mu-bsu-hF-FMK and Mu-F-hF-FMK sur-
vived throughout the experiment (18 d). The levels of par-
asitemia were lowest in mice treated with Mu-F-hF-FMK
and ranged from 10–500 trypomastigotes per milliliter of
blood. This corresponded to a reduction of 3 log units
from untreated controls. Mice treated with the related but
less effective (in protease substrate assays) dipeptide inhibi-
tor Mu-bsu-hF-FMK had persistent high parasitemia in the
range of 4 3 104–5 trypomastigotes per milliliter of blood.
Not only was Z-F-A-FMK ineffective, but mice had
higher parasitemia and died earlier than controls.
From tissue culture screens (Tables 1 and 2), vinyl sul-
fone derivatized pseudopeptides with high efficacy but less
toxicity than FMK inhibitors were selected for further
evaluation in a mouse model of acute Chagas’ disease. The
effect of CPI-treatment on the survival of T. cruzi in-
fected C3H mice is shown in Table 3. Untreated controls
infected with a very high dose (4 3 106) of tissue culture–
derived trypomastigotes all died by 4–5 d after infection.
All five mice treated with Mu-F-hF-VSf survived for 14–
16 d at which time the experiment was terminated and an-
Figure 1. Levels of parasitemia and survival of mice treated with pepti-
domimetic fluoromethyl ketones. CH3 mice were infected with T. cruzi
and treated twice daily with 1 mg i.p. of Z-F-Ala-FMK (d); Mu-bsu-hF-
FMK (s); Mu-F-hF-FMK (n); and controls with and without DMSO i.p.
(h, j). Parasitemias were determined every 48 h in each animal on al-
ternating days. Results are mean of two to three animals per day.
Table 3. Treatment of T. cruzi–infected C3H Mice with Cysteine Protease Inhibitors
Experiment Inhibitor (CPI) Number of mice
Inoculum
(trypomastigotes)
Number of mice
rescued* from
lethal infection
Maximal
Survival
d
1‡ Control 5 mice per lot 4 3 106 — 5
Mu-F-hF-FMK 0/5 10
Mu-F-hF-VSf 5/5 .16§
2‡ Control 6 mice per lot 1 3 106 — 10
Mu-F-hF-FMK 5/6 18
Mu-F-hF-VSf 6/6 .180i
3¶ Control 6 mice 1 3 105 22
N-Pip-F-hF-VSf 10 mice 10/10 .240**
Effect of cysteine protease inhibitors on the survival of T. cruzi–infected mice. In these series of independent experiments, T. cruzi–infected, C3H
mice were treated with Mu-F-hF-FMK, Mu-F-hF-VSf, and N-Pip-F-hF-VSf at the doses and regimens indicated. Controls were inoculated intra-
peritoneally with an equal volume of DMSO solution or not injected.
*“Rescued” defined as surviving at least 7 d after all controls died.
‡Animals treated with 1 mg CPI twice a day (100 mg/kg/d).
§Experiment stopped at 16 d.
i2/6 animals survived .180 d after infection when experiment was stopped. Blood smears were negative and hemo-cultures were positive.
¶Animals treated with 0.7 mg CPI three times a day.
**6/10 animals survived .240 d after infection; 3/6 mice were both blood smear and hemo-culture negative.
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imals killed (Table 3, Experiment 1). When the infectious
dose was reduced to 1 3 106 T. cruzi trypomastigotes and
mice treated with one 24-d regimen of Mu-F-hF-VSf,
two out of six mice survived up to 180 d after infection at
which time the experiment was terminated (Table 3, Ex-
periment 2).
From these pilot studies, the most promising lead com-
pound was then evaluated in a new dosing regimen based
on a pharmacokinetics analysis of Mu-F-hF-VSf (25).
Mice were treated three times daily with 2.1 mg/d i.p. of
N-Pip-F-hF-VSf (Table 3, Experiment 3). As indicated in
Table 3, all 10 mice survived at least 7 d longer than un-
treated mice and 6 out of 10 mice survived over 270 d after
infection. Three of the six long-term surviving mice had
consistently negative blood-parasite cultures over the entire
treatment period while the remaining three out of six were
still positive, although well below controls. After being al-
lowed to establish chronic infection for 3 mo, this latter
group of 3 mice were retreated with 2.1 mg/d i.p. of
N-Pip-F-hF-VSf for 21 d (Table 4, Experiment 4). Blood
cultures (10–50 ml) were negative for the retreated animals.
In summary, 5 of 10 treated mice from this study have now
survived for 9 mo without symptomatology and with nega-
tive parasitemia and hemocultures (one mouse died of acci-
dental trauma after 100 d). Similar results were obtained
with 3-wk-old outbred Swiss mice weighing initially 19–
21 g (data not shown).
In the studies described above, CPI treatment did not in-
duce gross or microscopic abnormalities in either infected
or uninfected mice. To further assess toxicity, doses of 4
mg/d i.p. of Mu-F-hF-VSf and 12 mg p.o. of N-Pip-F-
hF-VSf for 4 d were also evaluated. No gross or micro-
scopic abnormalities were observed in necropsied animals.
Confirmation that CPI Enters Amastigotes and Targets
Cruzain. CPI have been shown to produce a characteris-
tic Golgi abnormality in the extracellular epimastigote stage
of T. cruzi (21).
To confirm that the same effect was produced in the
treated amastigotes, amastigotes within host macrophages
that had been treated with Mu-F-hF-VSf (10 mM) for 48 h
were examined after labeling with Bodipy FL ceramide that
accumulates in the Golgi compartment. Cells were ob-
served by contrast phase (Fig. 2, A and B) and fluorescence
microscopy (Fig. 2, C and D). No Bodipy FL labeling was
apparent in untreated intracellular amastigotes (Fig. 2 C),
whereas the larger Golgi complex (G) of untreated host
cells was visible. In contrast, the Golgi apparatus (g) of Mu-
F-hF-VSf–treated amastigotes had abnormally large, fluo-
rescent vesicles consistent with ultrastructural alterations in
the Golgi complex previously observed in treated epimas-
tigotes (Fig. 2 D). To confirm these results, the normal
morphology of control intracellular amastigotes (Fig. 3 A)
was compared with the ultrastructure of CPI-treated tissue
culture amastigotes (Fig. 3 B). Golgi complex and cytoplas-
mic vesicle alterations found in amastigotes (Fig. 3 B) re-
sembled those described for the epimastigote stage, and
consisted of significant dilation of cisternae (21). Similar ul-
trastructural alterations were evident in amastigotes isolated
from heart muscle of T. cruzi–infected mice treated with
Mu-F-hF-VSf (Fig. 3 C). The amounts of cruzain ex-
pressed on the surface of Mu-F-hF-VSf–treated and un-
treated amastigotes were quantified by immunoelectronmi-
croscopy (Fig. 4). A marked decrease in cruzain expressed
on the cell surface of CPI-treated cells (Fig. 4 B) was evi-
dent compared with untreated amastigotes (Fig. 4 A).
T. cruzi intracellular amastigotes were incubated with or
without cold inhibitor before incubation labeling with
[14C]Mu-F-hF-VSf. T. cruzi epimastigotes and recombi-
nant cruzain were also radiolabeled and autoradiographed
as standards (Fig. 5 A). 14C-inhibitor labeling of amastigote
cruzain (lane 1) was abolished by preincubation with unla-
beled Mu-F-hF-VSf (lane 2). In amastigotes isolated from
infested host cells two protease species were labeled. One
comigrated with the epimastigote cruzain species (z50 kD)
known to contain both the catalytic and COOH-terminal
domains (13) while the second comigrated with recombi-
nant cruzain containing only the catalytic domain and with a
macrophage protease (z30 kD).
Table 4. Treatment of Chronically Infected C3H Mice with N-Pip-F-hF-VSf
Experiment
Number of
chronically
infected mice Treatment Hemoculture* (Number of mice)
Survival
after injection
d
4 3‡ N-Pip-F-hF-VSf Positive before treatment (3/3) 300
Negative after treatment (2/3)
3§ No Negative (3/3) 300
Retreatment of three mice from Table 3 Experiment 3 that had entered chronic phase of disease but remained hemoculture positive. A 21-d oral
regimen of 0.7 mg TID N-Pip-F-hF-VSf was used.
*Macrophage hemocultures were described in Materials and Methods.
‡Chronically infected mice from Table 3 Experiment 3 retreated with i.p. regimen.
§Mice treated only as in Table 3 Experiment 3 but remaining hemoculture negative.
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Discussion
High toxicity and low efficacy make current chemother-
apy for Chagas’ disease highly unsatisfactory. Moreover,
commercial nifurtimox production has been discontinued
and benznidazole is at present the only treatment available.
Until recently, it was still controversial as to whether drug
treatment would have any effect on the more common
chronic stage of Chagas’ disease because it was unclear
whether parasites were still present. However, there is now
a clear association between parasitic burden and degree of
myocardial damage (26). A recent follow up study in Ar-
gentina of benznidazole-treated versus untreated chronic
chagasic patients showed less cardiomyopathy in the first
group (27). Electrocardiogram patterns of benznidazole-
treated patients confirmed an important reduction in dis-
ease progression (27). Andrade et al. (28) reported a corre-
lation between heart disease and persistent parasitemia in
mice. These studies emphasize the importance of the de-
velopment of more effective and less toxic chemotherapy
for both the acute and the chronic phase of Chagas’ disease.
We have targeted cruzain (a.k.a. cruzipain, gp57/51),
the major cysteine protease of T. cruzi (reviewed in 13, 29,
30), for the development of new chemotherapy. Previously
tested dipeptide-based cruzain inhibitors that mimic sub-
strate (20) were further modified to increase affinity for the
catalytic site of cruzain, increase half-life in vivo, provide
oral bioavailability, and reduce toxicity. In a previous re-
Figure 2. Treatment of T. cruzi–infected macrophages with a cysteine protease inhibitor and a fluorescent probe specific for the Golgi complex. Phase
contrast (A) and fluorescence (C) microphotograph of an untreated T. cruzi–infected macrophage. Several intracellular amastigotes are visible within the
cytoplasm of the host cell. The Golgi complex (G) of the host cell is labeled. Bodipy FL does not induce visible fluorescence in the Golgi complex of un-
treated amastigotes. Phase contrast (B) and fluorescence microphotograph (D) of an infected macrophage treated with 20 mM Mu-F-hF-VSf for 48 h.
Large, fluorescent Golgi vesicles (g) are evident in CPI-treated amastigotes indicative of vesicle dilation abnormality (21). a, amastigote; G, macrophage–
Golgi complex; g, amastigote–Golgi complex; N, macrophage nucleus.
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port, we showed that these CPI induced death in the extra-
cellular epimastigote stage of T. cruzi as a consequence of
blocking the autocatalytic processing of cruzain precursor
protein. This resulted in Golgi complex and endoplasmic
reticulum abnormalities secondary to accumulation of un-
processed cruzain precursor molecules in the vesicle com-
partments (21). We now present evidence that these CPI
also inhibit T. cruzi amastigote growth within macrophages
by the same mechanism. Among the inhibitors tested, Mu-
F-hF-VSf most effectively blocked the intracellular cycle
Figure 3. Electronmicroscopy of T. cruzi intracellular amastigotes. T. cruzi amastigotes observed within culture macrophages (A and B) or heart muscle
of Mu-F-hF-VSf–treated mice (C). The normal ultrastructure of untreated intracellular amastigotes within irradiated macrophages (A) contrasts with the
altered morphology of intracellular amastigotes treated with 20 mM of Mu-F-hF-VSf for 48 h (B). More dilated Golgi vesicles and perinuclear mem-
brane similar to that reported in treated epimastigotes (21). Similar ultrastructural alterations were observed in amastigotes isolated from heart muscle (C)
of experimentally infected mice treated with 2 mg/d i.p. Mu-F-hF-VSf for 4 d before necropsy and isolation of heart muscle. A, Untreated amastigotes;
B, CPI-treated cell culture amastigote; C, amastigote infecting the heart muscle of a CPI-treated animal. Nuclear membrane (large arrows); Golgi complex
(small arrow); vesicle (m). No abnormalities were noted in Golgi complex or other organelles of host cells. Bar, 1 mm.
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of the parasite (Table 2) and resulted in amastigote death in
vitro. None of the inhibitors produced abnormalities in the
host cells at the concentrations necessary to interrupt the
parasite life cycle.
Subsequent testing of a number of CPI in an experimen-
tal mouse model of acute Chagas’ disease showed that the
inhibitors also disrupted the life cycle of T. cruzi in vivo.
Initially, T. cruzi–infected animals were treated with the
fluoromethyl ketone–derivatized peptidomimetics Mu-
F-hF-FMK, Mu-bsu-hF-FMK, and Z-F-A-FMK (Fig. 1).
Treatment with Mu-F-hF-FMK reduced parasitemia by 3
log units which resulted in the survival of infected mice
throughout the experiment, terminated 18 d after infection.
In contrast, animals treated with Mu-bsu-hF-FMK, a less
effective inhibitor of the protease itself, and Z-F-A-FMK, a
peptide with natural amino acids, had z100- and 10,000-fold
higher parasitemias, respectively. Survival in the Z-F-A-
FMK group (8 d) was significantly lower than in controls
(12 d). The increased mortality and parasitemia probably
result from a toxic metabolite of the natural amino acid in-
hibitor. Z-F-A-FMK is cleaved between the phenylalanine
and alanine in vivo by an as yet unknown mammalian pro-
tease releasing alanine-FMK which, in turn, enters and in-
hibits the Krebs cycle (31). This fluoride-dependent toxic-
ity results in hypothermia in mice, and T. cruzi has a higher
growth rate at 358C than at 378C (32, 33). The peptidomi-
metics containing at least one nonnatural amino acid ana-
logue (e.g., hF) do not undergo this cleavage and metabo-
lism (25). To completely avoid the potential toxicity of
FMK derivatives, vinylsulfone analogues were tested and
found to extend survival to 120–180 d after infection with
106 trypomastigotes. We further evaluated the more aque-
ous soluble derivative N-Pip-F-hF-VSf that is absorbed
after oral dosing. 5 out of 10 treated mice have now sur-
vived for over 9 mo, 4 of them with repeatedly negative
hemocultures indicative of parasitological cure. No toxicity
was observed at doses two- to sixfold higher than the ther-
apeutic doses administered p.o. or intraperitoneally for 20 d
or when mice were treated for 45 d with the therapeutic
dose of 2 mg/d inhibitor.
To elucidate the mechanism of action of CPI versus in-
tracellular amastigotes, the pathogenic stage of T. cruzi, we
Figure 4. Immunoelectronmicroscopy of cell surface membranes of T.
cruzi amastigotes. Cell surface membranes of untreated (A) and Mu-F-hF-
VSf–treated (B) amastigotes were immunocytochemically labeled with a
specific anti-cruzain antibody. Note markedly diminished gold label on
surface of treated parasite consistent with retention of unprocessed cruzain
in Golgi (21). PM, parasite cell surface membrane; IGL, immunogold la-
bel. Bar, 0.2 mm.
Figure 5. Autoradiogram of ex-
tract from radiolabeled [14C]Mu-
F-hF-VSf intracellular amasti-
gotes. Binding of the radiolabeled
inhibitor to amastigote cruzain
was abolished by preincubation
with unlabeled Mu-F-hF-VSf
followed by [14C]CPI. Epimas-
tigote cruzain and recombinant
cruzain controls are shown as
standards. Note two species la-
beled in amastigotes that comi-
grate with either epimastigote
cruzain (50 kD) which has both
catalytic and COOH-terminal
domains (13) or with recombi-
nant cruzain (30 kD) that only has
catalytic domain. Lane 1, T. cruzi
intracellular amastigotes labeled
with [14C]CPI; lane 2, T. cruzi in-
tracellular amastigotes preincu-
bated with unlabeled inhibitor;
lane 3, sample buffer; lane 4, re-
combinant cruzain labeled with
[14C]CPI; lane 5, epimastigotes radiolabeled with [14C]Mu-F-hF-VSf.
Note 57/51-kD doublet characteristic of native cruzain which retains
COOH-terminal domain (13). Recombinant cruzain lacks the COOH-
terminal domain (14).
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infected host cells whose cell cycles were arrested. Intracel-
lular amastigotes treated with Mu-F-hF-VSf showed major
morphological alterations as early as 24–48 h after treat-
ment, and macrophage cultures were amastigote free within
12 d. Mu-F-hF-VSf produced abnormalities in the protein
trafficking pathway (nuclear membrane, ER, Golgi com-
plex) and induced the appearance of double-membrane
vacuoles with similar morphology to autophagosome vacu-
oles (Fig. 3). Cruzain normally localizes to the cell surface
and lysosome membrane of T. cruzi amastigotes (34, 35).
CPI treatment significantly reduced the amounts of cruzain
appearing both on the cell membrane (Fig. 4) and in the ly-
sosome consistent with an arrest of cruzain transport. An
increase of fluorescence with Bodipi FL of the Golgi com-
plex in treated amastigotes was similar to that described for
epimastigotes and correlated with enlargement of the Golgi
complex secondary to retention of unprocessed cruzain
(Fig. 2; reference 21). Radiolabeled inhibitor was used to
confirm entry into amastigotes and specific labeling of the
target protease cruzain (Fig. 5). The absence of any host
cell or animal toxicity at therapeutic doses suggests that the
parasites are more susceptible to inhibitor perhaps because
of the redundancy of cysteine proteases in mammalian cells
versus the parasite.
We have identified peptidomimetic cysteine protease in-
hibitors that consistently rescued mice from acute lethal in-
fections of T. cruzi, reduced parasitemia by up to 3 log
units, and cured mice in the chronic stage of disease treated
by a 21-d regimen. These results provide an important
“proof of concept” for the development of cysteine pro-
tease inhibitors as chemotherapy for a number of disease
entities including cancer cell invasion, inflammation, os-
teoporosis, and microbial infections where cysteine pro-
teases are thought to play a key role in pathogenesis (36).
Although further improvements on vinyl sulfone inhibitor
leads should be forthcoming, they clearly demonstrate that
animals can tolerate CPI at concentrations and dosing
schedules that eliminate an intracellular parasite. The phar-
macokinetics of these inhibitors were adequate to sustain
therapeutic levels and the N-methyl piperazine derivative
demonstrated oral bioavailability. The efficacy and lack of
toxicity of CPI in treating both acute and chronic T. cruzi
infections supports a call for further development of these
leads.
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